Dr. S. Venkatesan MD

APRIL 18, 2024

Lowering the raised LA mean pressure is a major therapeutic goal in any severely symptomatic left heart disease, whether it is valvular or myocardial disease. It is prudent to understand, that even in systolic LV failure; it is the raised LVEDP that causes the symptoms and marks the limits of exercise capacity.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Pulmonary Congenital Heart Disease VSD 40

DAIC

FEBRUARY 29, 2024

24: Joint American College of Cardiology/Journal of the American College of Cardiology Late-Breaking Clinical Trials (Session 402) Saturday, April 6 9:30 – 10:30 a.m.

Aortic valve 103

Aortic valve Myocardial Infarction Aortic Blood Pressure 103

DAIC

JUNE 26, 2024

The analysis sought to determine whether phenotypic features and treatment effects of semaglutide vary by sex in obesity-related heart failure ( HF ) with preserved ejection fraction (HFpEF). Our study sheds light on these differences and the consistent benefits of semaglutide for women and men.”

Preserved Ejection Fraction 105

Preserved Ejection Fraction Obesity BMI Heart Failure 105

DAIC

APRIL 9, 2024

Maron, MD “Our findings provide enthusiasm that a novel drug therapy with ninerafaxstat may provide nonobstructive HCM patients an opportunity to achieve a better quality of life by decreasing symptom burden and improving exercise capacity,” said Martin S. The safety and tolerability of the drug in this phase 2 trial was excellent.

Cardiomyopathy 52

Cardiomyopathy Quality of Life Chest Pain Preserved Ejection Fraction 52

Cardiometabolic Health Congress

JULY 25, 2023

There are significant data that show that if you have obesity, you have a high risk of developing coronary heart disease, heart failure, type 2 diabetes (T2D) or risk factors such as hypertension and dyslipidemia. [1] What levels of exercise intensity or duration are beneficial? Is the obesity paradox a real phenomenon?

Obesity 52

Obesity BMI Heart Failure Cardiovascular Disease 52